Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

OncoMed Shares Jump After Signing Deal With Celgene

OncoMed Pharmaceuticals Inc., a drug developer that first sold shares to the public in July, almost doubled in trading after signing a $177.25 million agreement with Celgene Corp. on as many as six potential cancer medicines.

OncoMed rose 98 percent to $27.70 at the close in New York in the biggest one-day rise since the company’s initial public offering. The shares of the Redwood City, California-based company have gained 63 percent since the IPO.

The deal includes a $22.25 million equity investment and additional payments tied to development and sales goals which may total more than $3 billion, the companies said today in a statement. OncoMed, whose drugs target cancer stem cells, will oversee early clinical studies, and Summit, New Jersey-based Celgene will then have the option to license worldwide rights to the compounds.

Celgene, the world’s fourth-largest biotechnology company, gets an exclusive option on OncoMed’s demcizumab, which is in early stage studies in diseases including pancreatic cancer. Celgene shares, which have doubled this year, declined 2 percent to $159.93.

OncoMed was advised by Latham & Watkins LLP and Leerink Swann LLC. The company also has partnerships with Bayer AG and GlaxoSmithKline Plc.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.